Compare Slide Insurance Holdings Inc. Common Stock (SLDE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Slide Insurance Holdings Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Slide Insurance Holdings Inc. Common Stock trades at $25.84 (market cap $3.00B), while State Street SPDR S&P Biotech ETF trades at $147.52 (market cap $10.27B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 3.4× Slide Insurance Holdings Inc. Common Stock's market cap, and Slide Insurance Holdings Inc. Common Stock pays a 1.09% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Slide Insurance Holdings Inc. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| SLDE | XBI | |
|---|---|---|
Market Cap | $3.00B | $10.27B |
Volume | 1,061,663 | 9,751,587 |
Sector | Financials | Broad Market / Factor |
52-Week High | $26.48 | $169.55 |
52-Week Low | $14.38 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $1.80B | — |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLDE trades at $25.50, down slightly (-0.12%) on the day, with strong fundamental metrics including a P/E of 6.16 and net income margin of 40.02%. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results scheduled for October 27, 2026. Revenue growth from $1.16B in 2025 to projected $1.4B in 2026 demonstrates solid business momentum, supported by expanded insurance offerings in key markets.
The stock presents attractive value with strong profitability and analyst support (80% buy ratings), though hurricane exposure in Florida remains a key risk. Current price sits near consensus target of $25.00, suggesting limited near-term upside but solid fundamentals for long-term investors. Management's share repurchase program and dividend initiation provide additional shareholder value support.
XBI trades at $146.8, down 3.04% today, with a bearish technical signal driven by selling pressure in moving averages. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than diversified healthcare funds.
Outlook remains mixed with neutral analyst consensus but positive sector catalysts. Opportunities include biotech innovation and M&A potential, while risks involve high volatility, regulatory uncertainty, and expense ratios above broader healthcare ETFs. Investors should weigh targeted biotech exposure against sector-wide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Slide Insurance Holdings Inc. Common Stock
Slide Insurance Holdings, Inc. is a technology-enabled insurance company based in Florida that underwrites coastal specialty personal lines insurance, including homeowners and condominium unit owner policies, and also provides reinsurance and insurance agency services.
Read more on SLDE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
